TR1 Notification of Major Interest

26th October 2016 - 12:45 pm

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP (“Lanstead”). Lanstead’s holding in ImmuPharma is now confirmed at a total of 10,521,555 Ordinary Shares which equates to a current position in the Company of 8.4%.

For full disclosure of the TR1 click here

Share this article

Leave a comment